<DOC>
	<DOCNO>NCT00386373</DOCNO>
	<brief_summary>Primary Objective : 1 . To assess safety toxicity imatinib mesylate give patient Ph ( + ) CML , ALL AML within first 100 day follow allogeneic bone marrow stem cell transplantation . Secondary Objectives : 1 . To identify clinically significant drug interaction imatinib post-transplant setting . 2 . To develop specific monitor parameter imatinib use utilized early post-BMT setting . 3 . To record one-year survival data patient cohort ass effect early imatinib administration endpoint .</brief_summary>
	<brief_title>Use Tolerability Imatinib Mesylate ( Gleevec ) Leukemia Patients</brief_title>
	<detailed_description>Imatinib mesylate FDA-approved , commercially available drug patient acute chronic leukemia carry Philadelphia chromosome . Women able child must negative blood pregnancy test take drug No earlier three week bone marrow stem cell transplant , start take imatinib mesylate mouth . You take twice day roughly 100 day follow transplant release Houston area M. D. Anderson physician . Imatinib mesylate take meal glass water , preferably morning . The dose gradually increase long n't experience severe side effect . If severe side effect occur , imatinib stop , either temporarily permanently . After 100 day ( leave Houston ) medication may continue discretion study doctor , study consider complete . This investigational study . A total 40 patient take part study . All enrol M. D. Anderson . The study partially fund manufacturer imatinib mesylate ( see ) , although drug provide free charge .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>1 . Patients Ph ( + ) CML and/or CML bcrabl rearrangement diploid cytogenetics eligible protocol high priority ( e.g . ID02901 , DM99081 , DM97206 , etc ) . 2 . The disease must beyond first chronic phase accord IBMTR criterion ( i.e . accelerated phase , blastic phase , second chronic phase ) time transplant . 3 . Patients Ph ( + ) acute lymphocytic ( myeloid ) leukemia . 4 . Patients diploid cytogenetics molecular evidence bcrabl rearrangement also eligible . 5 . Age &gt; /= 16 year 6 . Unsupported ANC least 1500 unsupported platelet count least 50K follow BMT . 7 . Patients may receive prior chemotherapy disease previously untreated . 8 . Patients must receive allogeneic bone marrow stem cell transplant . Allogeneic transplant type may include matched sibling donor , mismatch related donor , unrelated donor . All preparative regimen acceptable . 9 . Signed informed consent 10 . Zubrod status &lt; /= 3 11 . Adequate hepatic ( bilirubin &lt; /= 3 mg/dl , transaminases &lt; 4 x upper limit normal ) renal function ( serum creatinine &lt; /= 3 mg/dl ) 1 . Grade III/IV cardiac problem define NYHAC 2 . History hypersensitivity imatinib 3 . Pregnant lactate woman 4 . HIV positive</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Chronic Myeloid Leukemia</keyword>
	<keyword>CML</keyword>
	<keyword>ALL</keyword>
	<keyword>AML</keyword>
	<keyword>Leukemia</keyword>
	<keyword>Imatinib Mesylate</keyword>
	<keyword>Gleevec</keyword>
	<keyword>Philadelphia-Positive</keyword>
	<keyword>Bone marrow transplant</keyword>
	<keyword>BMT</keyword>
	<keyword>Stem cell transplant</keyword>
	<keyword>SCT</keyword>
</DOC>